# Effect of Glycopyrronium on Morning Symptoms and Pulmonary Function in Patients With Moderate to Severe COPD

> **NCT01959516** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 124 (actual)

## Conditions studied

- COPD

## Interventions

- **DRUG:** Glycopyrronium
- **DRUG:** Tiotropium
- **DRUG:** Placebo to glycopyrronium
- **DRUG:** Placebo to tiotropium

## Key facts

- **NCT ID:** NCT01959516
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02
- **Primary completion:** 2014-10
- **Final completion:** 2014-10
- **Target enrollment:** 124 (ACTUAL)
- **Last updated:** 2016-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01959516

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01959516, "Effect of Glycopyrronium on Morning Symptoms and Pulmonary Function in Patients With Moderate to Severe COPD". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01959516. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*